Tokyo, Japan

Yoshiteru Eikyu

USPTO Granted Patents = 8 


Average Co-Inventor Count = 7.2

ph-index = 3

Forward Citations = 37(Granted Patents)


Location History:

  • Ikeda, JP (1999 - 2000)
  • Nara, JP (2005 - 2007)
  • Osaka, JP (2004 - 2008)
  • Tokyo, JP (2009 - 2010)

Company Filing History:


Years Active: 1999-2010

Loading Chart...
Loading Chart...
8 patents (USPTO):

Title: Yoshiteru Eikyu: Innovator in Pharmaceutical Compounds

Introduction

Yoshiteru Eikyu is a prominent inventor based in Tokyo, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that inhibit histone deacetylase (HDAC). With a total of 8 patents to his name, Eikyu's work has the potential to impact therapeutic approaches for various diseases.

Latest Patents

One of Eikyu's latest patents focuses on pyrazinyl hydroxyacrylamide compounds that exhibit an inhibitory effect on the activity of histone deacetylase. This invention pertains to novel N-hydroxyacrylamide compounds and their pharmaceutically acceptable salts, which serve as HDAC inhibitors. The patent outlines a pharmaceutical composition that includes these compounds and describes methods for their therapeutic use in treating and preventing HDAC-related diseases.

Career Highlights

Throughout his career, Yoshiteru Eikyu has worked with notable companies in the pharmaceutical industry. He has been associated with Fujisawa Pharmaceutical Company, Ltd. and Astellas Pharma GmbH, where he has contributed to various innovative projects and research initiatives.

Collaborations

Eikyu has collaborated with esteemed colleagues, including Hisashi Takasugi and Kazuhiko Take. These partnerships have fostered a collaborative environment that enhances the development of groundbreaking pharmaceutical solutions.

Conclusion

Yoshiteru Eikyu's contributions to the field of pharmaceuticals, particularly through his innovative patents, highlight his role as a key inventor in the industry. His work continues to pave the way for advancements in the treatment of HDAC-related diseases.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…